Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299-1307.
Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8:629-638.
Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-130.
Ott C, Liebold A, Takses A, et al. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract. 2012;2012:595970.
Khan N, Patel D, Shah Y, et al. Factors predicting testing and treatment of iron deficiency in a nationwide cohort of anemic UC patients. Inflamm Bowel Dis. 2016;22:2894-2901.
Patel D, Yang YX, Trivedi C, et al. Incidence, duration, and management of anemia: a nationwide comparison between IBD and non-IBD populations. Inflamm Bowel Dis. 2019. [Epub ahead of print]
Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-222.
World Health Organization. Nutritional Anemias: Tools for Effective Prevention and Control. https://apps.who.int/iris/bitstream/handle/10665/259425/9789241513067-eng.pdf?sequence=1. Published 2017. Accessed October 2019.
Hou JK, Gasche C, Drazin NZ, et al. Assessment of gaps in care and the development of a care pathway for anemia in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23:35-43.
Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91:31-38.
Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease–a practical approach. Ann Gastroenterol. 2013;26:104.
Infusino I, Braga F, Dolci A, et al. Soluble transferrin receptor [sTfR] and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia: a metanalysis. Am J Clin Pathol. 2012;138:642-649.
Forman DT, Parker SL. The measurement and interpretation of serum ferritin. Ann Clin Lab Sci. 1980;10:345-350.
Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579-588.
Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44:259-270.
Mayo Clinic. Drugs and Supplements: Iron Supplements (Oral Route, Parenteral Route). https://www.mayoclinic.org/drugs-supplements/ironsupplement-oral-route-parenteral-route/proper-use/drg-20070148. Updated November 1, 2019. Accessed October 31, 2019.
Hallberg L, Hulthen. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr. 2000;71:1147-1160.
Cook JD, Monsen ER. Vitamin C, the common cold, and iron absorption. Am J Clin Nutr. 1977;30:235-241
Lam JR, Schneider JL, Quesenberry CP, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152:821-829.e1.
Hallberg L, Rossander L, Skånberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr. 1987;45:988-996.
Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. Gut. 1975;16:193-200.
Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2013;6:61.
Silva AF, Schieferdecker ME, Amarante HM. Food intake in patients with inflammatory bowel disease. Arq Bras Cir Dig. 2011;24:204-209.
Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29:291-303.
Rampton DS, Goodhand JR. Joshi NM, et al. Oral iron treatment response and predictors in anaemic adolescents and adults with IBD: a prospective controlled open-label trial. J Crohn's Colitis. 2017;11:706-715.
Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10:e0117383.
Danese S, Hoffman C, Vel S, et al. Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn's and Ulcerative Colitis Association's online survey. Eur J Gastroenterol Hepatol. 2014;26: 1385-1391.
Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1058-1065.
Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44:838-845.
Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT®) randomized controlled trial. Am J Gastroenterol. 2008;103:1182.
Schrӧder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open label, multicenter study. Am J Gastroenterol. 2005;100:2503.
Avni T, Bieber A, Steinmetz T, et al. Treatment of anemia in inflammatory bowel disease---systematic review and meta-analysis. PLoS One. 2013;8:e75540.
Hougen I, Collister D, Bourrier M, et al. Safety of intravenous iron in dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;13:457-467.
Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anaemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Med Baltim. 2016;95:e2308.
Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis? J Crohns Colitis. 2012;6:267-275.
Askan A, Isik H, Radeke A, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303-1318.
Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104:1460-1467.
Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16-30.
Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683-690.
Avni T, Bieber A, Grossman A, Green H, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12-23.
Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015;172:5025-5036.
Yessayan L, Sandhu A, Besarab A, et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol. 2013;2013:703038.
Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062-2068.
Wolf M, Chertow GM, Macdougall IC, et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23).
Barish CF, Koch T, Butcher A, et al. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized controlled trials. Anemia. 2012;2012:172104.
Ifie E, Oyibo SO, Joshi H, et al. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. 2019;2019(1).
Blazevic A, Hunze J, Boots JMM. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72:49-53.
Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep. 2017. pii: bcr2016219160.
Klein K, Asaad S, Econs M, et al. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018. pii: bcr-2017-222851.
DeLoughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019;142:8-12.
Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017;66:863-871.
Macdougall IC, White C, Anker SD, et al; PIVOTAL Investigators and Committees. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380:447-458.
Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:269-277.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Gil Y. Melmed, MD, MS

Professor of Medicine
Director, Inflammatory Bowel Disease Clinical Research
Co-director, Inflammatory Bowel Disease
Cedars-Sinai Medical Center
Los Angeles, California

Disclosures

Disclosure: Gil Y. Melmed, MD, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie, Celgene, Janssen, Pfizer, Samsung Bioepis, Takeda

Editor

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance , Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / ABIM MOC / CE

Clinical Decision Making in Patients With IDA and IBD

Authors: Gil Y. Melmed, MD, MS
CME / ABIM MOC / CE Released: 12/14/2019
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 12/14/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for gastroenterologists, primary care physicians, hematologists, and nurses.

The goal of this activity is to improve clinicians' competence related to screening for iron deficiency anemia (IDA) in patients with inflammatory bowel disease (IBD) and selecting appropriate therapies to improve patients' symptoms and quality of life.

Upon completion of this activity, participants will:

Have increased knowledge regarding the:
- Diagnostic criteria for iron deficiency and anemia
Demonstrate greater competence in their ability to:
- Initiate a treatment strategy for IDA in patients with IBD
- Assess treatment response in patients with IDA
- Adjust treatments for patients with IBD and IDA when appropriate

Disclosures

Faculty

Gil Y. Melmed, MD, MS

Professor of Medicine
Director, Inflammatory Bowel Disease Clinical Research
Co-director, Inflammatory Bowel Disease
Cedars-Sinai Medical Center
Los Angeles, California

Disclosures

Disclosure: Gil Y. Melmed, MD, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie, Celgene, Janssen, Pfizer, Samsung Bioepis, Takeda

Editor

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance , Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.00 contact hour(s) of continuing nursing education for RNs and APNs; 1.00 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

Case 1: Julie, a 33-Year-Old Woman Recently Diagnosed With Ulcerative Colitis

Julie is a 33-year old woman with mild UC that was diagnosed 6 months ago. She recently accepted a job at a law firm in your city and has just moved from out of state. She comes to your office as a new patient and wants to establish care for her UC at your center. You review her history and workup provided by her previous physician. Notably, she was placed on mesalamine therapy at the time of her UC diagnosis. She has been in clinical remission for 4 months. After reviewing Julie's records, you perform a physical examination. She appears to be in good health and has no symptomatic complaints.

Page 1 of 15

CME / ABIM MOC / CE Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Gil Y. Melmed, MD, MS

Editor

Roderick Smith, MS

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

CME / ABIM MOC / CE

Clinical Decision Making in Patients With IDA and IBD

Target Audience and Goal Statement

Disclosures

Faculty

Gil Y. Melmed, MD, MS

Editor

Roderick Smith, MS

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Clinical Decision Making in Patients With IDA and IBD

Case 1: Julie, a 33-Year-Old Woman Recently Diagnosed With Ulcerative Colitis